Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Intravenous Sodium Heparin UQ in Healthy Participants
NCT03125187Phase 1Suspended
- Sponsor
- União Química
- Start
- Feb 2021
- Primary completion
- Feb 2021
- Modality
- Pharmaceutical
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Heparina cálcica in venous thromboembolism (VTE) (2 arms), sponsored by União Química. Primary endpoint: activity of the anti-Xa factor at 8 hours. Started Feb 2021; status: suspended.
02
Drugs
Heparina cálcica
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03125187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125187.